Drug Profile
Dendroaspis natriuretic peptide
Latest Information Update: 10 Dec 2007
Price :
$50
*
At a glance
- Originator Mayo Clinic
- Class Amino acids
- Mechanism of Action Diuretics
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure
Most Recent Events
- 10 Dec 2007 Discontinued - Preclinical for Congestive heart failure in USA (unspecified route)
- 24 Aug 2006 No development reported - Preclinical for Congestive heart failure in USA (unspecified route)
- 19 Mar 2002 A study has been added to the Heart Failure pharmacodynamics section